The problems faced when assessing the prevalence and incidence of antiretroviral-related toxicities

Antiviral Therapy

Volumn 9, Issue 6, 2004, Pages 865-878

  Smith, Colette J ^a   Sabin, Caroline A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEMOGRAPHY; DRUG INDUCED DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INCIDENCE; LIVER TOXICITY; METABOLIC DISORDER; METHODOLOGY; OBSERVATION; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TIME; TOXICITY ENDPOINT; TOXICITY TESTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INCIDENCE; LIVER DISEASES; MALE; PREVALENCE;

EID: 11144278249     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN & Lundgren JN for the EuroSIDA study group. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725-1730.
2. Mocroft A, Ledergerber B, Katlama C, Kirk KA, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN & Lundgren JD. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
3. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ & Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 1998; 338:853-860.
4. Powderly WG. Long-term exposure to lifelong therapies. Journal of Acquired Immune Deficiency Syndromes 2002; 29:S28-S40.
5. Arenas-Pinto A, Grant AD, Edwards S & Weller IVD. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sexually Transmitted Infections 2003; 79:344.
6. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, Hoffmann M & Tebas P. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clinical Infectious Diseases 2003; 36:482-490.
7. Carr A & Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
8. Hewitt RG. Abacavir hypersensitivity reaction. Clinical Infectious Diseases 2002; 15:1137-1142.
9. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C & Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15:1848.
10. Sundar K. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Critical Care Medicine 1997; 8:1425-1430.
11. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JN & Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. AIDS 1999; 13:2075-2082
12. Sabin CA & Phillips AN. Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies. Journal of Antimicrobial Chemotherapy 2001; 47:371-375.
13. Rhew DC, Bernal M, Aguilar D, Iloeje U & Goetz MB. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clinical Infectious Diseases 2003; 37:959-972.
14. Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. Journal of Acquired Immune Deficiency Syndromes 2000; 25:S4-S11.
15. Wanke CA. Epidemiological and clinical aspects of the metabolic complications of HIV infection: the fat redistribution syndrome. AIDS 1999; 13:1287-1293.
16. John M, Nolan D & Mallal S. Editorial review: antiretroviral therapy and the lipodystrophy syndrome. Antiviral Therapy 2001; 6:9-20.
17. Drechsler H & Powderly WG. Switching effective antiretroviral therapy: a review. Clinical Infectious Diseases 2002; 35:1219-1230.
18. Murphy RL & Smith WJ. Switch studies: a review. HIV Medicine 2002; 3:146-155.
19. Safrin S & Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13:2493-2505.
20. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine 2003; 349:1993-2003.
21. Klein D, Hurley LB, Quesenberry CP & Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? Journal of Acquired Immune Deficiency Syndromes 2002; 30:471-477.
22. Mary-Krause M, Cotte L, Simon A, Parrisani M & Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-2486.
23. Bozzette SA, Ake CF, Tarn HK, Chang SW & Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. New England Journal of Medicine 2003; 148:702-710.
24. Coplan PM, Nikas A, Japour A, Cormier K, Maradit-Kremers H, Lewis R, Xu Y & DiNubile MJ. Incidence of myocardial infarction in randomised clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Research & Human Retroviruses 2003; 19:449-455.
25. Braitstein P, Yip B, Heath KV, Levy AR, Montaner JSG, Humphries K, Kiely FM, O'Shaughnessy MV & Hogg RS. Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995-2000. AIDS 2003; 17:2071-2075.
26. Friss-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN & Lundgren JD. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. AIDS 2003; 17:1179-1193.
27. Visnegarwala F, Darcourt J, Sajja P, Menon V, Ong O, Maldonado M & White AC. Changes in metabolic profile among antiretroviral-naive patients initiating protease inhibitor versus no-protease inhibitor containing HAART regimens. Journal of Acquired Immune Deficiency Syndromes 2003; 33:653-654.
28. Koppel K, Bratt G, Schulman S, Bylund H & Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2001; 29:441-449.
29. Collazos J, Mayo J, Ibarra S & Cazallas J. Hyperlipidemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection. AIDS 2003; 17:927-929.
30. Thiebaut R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercie P & Daucourt V. Serum triglycerides, HIV infection and highly active antiretroviral therapy, Acquitaine Cohort, France, 1996 to 1998. Journal of Acquired Immune Deficiency Syndromes 2000; 23:261-265.
31. Matthews GV, Moyle GJ, Mandalia S, Bower M, Nelson M & Gazzard BG. Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1 infected persons on initial therapy. Journal of Acquired Immune Deficiency Syndromes 2000; 24:310-315.
32. van Leth F, Phanuphak P, Gazzard B, Cahn P, Wood R, Bloch M, Katlama C, Schechter M, Murphy R, Horban A, Hall D, van der Valk M, Lange J & Reiss P. Lipid changes in a randomised comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirinz alone or both drug combined, together with stavudine and lamivudine (2NN study). 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, Mass., USA. Abstract 752.
33. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond M, Marcovina SM, Glauser MP, Nicod P, Darioli R & Mooser V for the Swiss HIV cohort. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100:700-705.
34. Behrens G, Deiam A, Schmidt H, Balks HJ, Brabant G, Korner T, Stoll M & Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63-F70.
35. Negredo E, Ribalta J, Parades R, Ferre R, Sirera G, Ruiz L, Salazar J, Reiss P, Masana L & Clotet B. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002; 16:1383-1389.
36. Piketty C, Peytavin G, Trylezinski A, Gonzalez-Canali G, Castiel P, Weiss L & Kazarchine MD. Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirinz. HIV Medicine 2002; 3:287-289.
37. Costa A, Pulido F, Rubio R, Cepeda C, Torralba M & Costa JR. Lipid changes in HIV-infected patients who started rescue therapy with an amprenavir/ritonavir-based highly active antiretroviral therapy. AIDS 2002; 16:1983-1984.
38. Lichenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC & Holmberg SD. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1 infected patients. Journal of Acquired Immune Deficiency Syndromes 2003; 32:48-56.
39. Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais J-P Sc Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. Journal of Acquired Immune Deficiency Syndromes 2001; 27:443-449.
40. van der Valk M, Gisolf EH, Wit FW, Japour A, Weverling GJ & Danner SA. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001; 15:847-855.
41. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
42. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Rinaldo C, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortes C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E & Gatell J. Substitution of nevirapine, efavirinz, or abacavir for Protease inhibitors in patients with human immunodeficiency virus infection. New England Journal of Medicine 2003; 349:1036-1046.
43. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP & Yeni P. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16:2447-2454.
44. Heath KV, Hogg R, Singer J, Chan KJ, O'Shaughnessy MV Sc Montaner JSG. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. Journal of Acquired Immune Deficiency Syndromes 2002; 30:440-447.
45. Hadigan C, Meigs JB, Corcoran C, Reitschel P, Basgoz N, Davis B, Sax P, Stanley T, Wilson PWF, D'Agostino RB & Grinspoon S. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clinical Infectious Diseases 2001; 32:130-139.
46. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ & Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet 1999; 353:2093-2099.
47. Tsiodras S, Mantzoros C, Hammer S Sc Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy. Archives of Internal Medicine 2000; 160:2050-2056.
48. Paparizos VA, Kyriakis KP, Botsis C, Papastamopoulos V, Hadjivassiliou M & Stavrianeas NG. Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus. AIDS 2000; 14:903.
49. Ruiz L, Negredo E, Domingo P, Parades R, Francia E, Balague M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange JMA & Clotet B. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomised, controlled study. Journal of Acquired Immune Deficiency Syndromes 2001; 27:229-236.
50. Matheron S, Descamps D, Boue F, Livrozet JM, Lafeuillade A, Aquilina C, Troisvallets D, Goetschel A, Brun-Vezinet F, Mamet JP & Thiaux C; CNA3007 Study Group. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antiviral Therapy 2003; 8:163-171.
51. Heath KV, Chan KJ, Singer J, O'Shaughnessy MV, Montaner JSG & Hogg RS. Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy. International Journal of Epidemiology 2002; 31:1016-1020.
52. Martinez E, Conget I, Lozano L, Casamitjana R & Gatell J. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13:805-810.
53. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P & Feingold KR. Lipids, lipoproteins, triglyceride clearence and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Journal of Clinical Endocrinology 6~ Metabolism 1992; 74:1045-1052.
54. Behrens GM, Meyer-Olson D, Stoll M & Schmidt RE. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 2003; 17:5149-5154.
55. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J & Pierson RN. Hypertriglyceridaemia in the acquired immunodeficiency syndrome. American Journal of Medicine 1989; 86:27-31.
56. Rodriguez-Guardado A, Maradona JA, Carton JA & Asensi V. Triglyceride increase can predict lipodystrophy in HIV patients under highly active antiretroviral therapy. AIDS 2003; 16:1434-1436.
57. Stone SF, Lee S, Keane NM, Price P & French MA. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. Journal of Infectious Diseases 2002; 186:1498-1502.
58. De Simone JA, Pomerantz RJ & Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Annals of Internal Medicine 2000; 133:447-454.
59. Pomerantz RJ. The expert speaks: immune reconstitution in AIDS. AIDS Patient Care & STDs 2003; 17:99-101.
60. Saves M, Vandentorren S, Daucourt V, Marimoutou C, Dupon M, Couzigou P, Bernard N, Mercie P & Dabis F. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. AIDS 1999; 13:115-151.
61. Gisolf EH, Dreezen C, Danner SA, Weel J & Weverling GJ. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Clinical Infectious Diseases 2000; 31:1234-1239.
62. d'Arminio Monforte A, Bugarini R, Pezzotti P, de Luca A, Antinori A, Mussini C, Vigevani M, Tirelli U, Bruno R, Gritti F, Piazza M, Chigiotti S, Chirianni A, De Stefano C, Pizzigallo E, Perrella O & Moroni M for the ICONA study group. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. Journal of Acquired Immune Deficiency Syndromes 2001; 28:114-123.
63. Aceti A, Pasquazzi C, Zechini B & De Bac C. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV. Journal of Acquired Immune Deficiency Syndromes 2002; 29:41-48.
64. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L & Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. Journal of Acquired immune Deficiency Syndromes 2001; 27:426-431.
65. Bonfanti P, Landonio S, Ricci E, Martinelli C, Fortuna P, Faggion I & Quirino T. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2001; 27:316-318.
66. Sulkowski MS, Thomas DL, Chaisson RE & Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. Journal of the American Medical Association 2000; 283:74-80.
67. den Brinker M, Wit FWNM, Wertheim-van Dillen PME, Jurriaans S, Weel J, van Leeuwen DM, Pakker NG, Reiss P, Danner SA, Weverling GJ & Lange JMA. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895-2902.
68. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia-Viejo MA, Mallolas J, Carne X, Phillips AN & Gatell J. Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15:1261-1268.
69. Saves M, Raffi F, Clevenbergh P, Marchou B, Walder-Combernoux A, Morlat P, Le Moing V, Riviere C, Chene G & Leport C for the APROCO Study Group. Hepatitis B or Hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. Antimicrobial Agents & Chemotherapy 2000; 44:3451-3455.
70. Wit FWNM, Weverling GJ, Weel J, Jurriaans S & Lange JMA. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. Journal of Infectious Diseases 2002; 186:22-31.
71. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE & Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-189.
72. Palmon R, Koo BCA, Shoultz DA & Dieterich DT. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. Journal of Acquired Immune Deficiency Syndromes 2002; 29:340-345.
73. Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, Spinetti A, Putzolu V, Casari S, Tomasoni L, Quiros-Roldan E, Favret M, Berchich L, Grigolato P, Callea F & Carosi G. Severe hepatotoxicity during combination antiretroviral therapy treatment: incidence, liver histology, and outcome. Journal of Acquired Immune Deficiency Syndromes 2003; 32:259-267.
74. Concato J, Shah N & Horwitz RJ. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New England Journal of Medicine 2000; 342:1887-1892.
75. Sabin CA. The role of observational studies in assessing the impact of antiviral therapies. Current Opinion in Infectious Diseases 2000; 13:631-635.
76. Dunn D, Babiker AG, Hooker M & Darbyshire JH. The dangers of inferring treatment effects from observational data: a case study in HIV infection. Controlled Clinical Trials 2002; 23:106-110.
77. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S & Sun E. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. New England Journal of Medicine 2002; 346:2039-2046.
78. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Issacs R, Hetherington S, Steel H & Spreen W. Abacavir-lamivudine-zidovudvne vs indinavir-lamivudine-zidovudine in antiretroviral naive HIV-infected patients: a randomised equivalence trial. Journal of the American Medical Association 2001; 285:1155-1163.
79. Ungsedhapand C, Kroon EDMB, Suwanagool S, Ruxrungtham K, Yimsuan N, Sonjai A, Ubolyam S, Buranapraditkun S, Tiengrim S, Pakker NG, Kunanusont C, Lange JMA, Cooper DA & Panuphak P. A randomised, open-label, comparative trial of zidovudine plus lamivudine vs zidovudine plus lamivudine plus didanosine in antiretroviral naive HIV-1-infected Thai patients. Journal of Acquired Immune Deficiency Syndromes 2001; 27:116-123.
80. Moore DA, Goodall RL, Ives NJ, Hooker M, Gazzard BG & Easterbrook PJ. How generalizable are the results of large randomized controlled trials of antiretroviral therapy? HIV Medicine 2000; 1:149-154.
81. Hankins C, Lapointe N & Walmsley S. Participation in clinical trials among women living with HIV in Canada. Canadian Women's HIV Study Group. Canadian Medical Association Journal 1998; 159:1359-1354.
82. Madge S, Mocroft A, Wilson D, Youle M, Phillips AN, Tyrer M, Cozzi-Lepri A, Swaden L & Johnson M. Participation in clinical studies among patients infected with HIV-1 in a single treatment centre over 12 years. HIV Medicine 2000; 1:212-218.
83. Gifford AL, Cunningham WE, Heslin KC, Andersen RM, Nakazono T, Lieu DK, Shapiro MF & Bozzette SA. Participation in research and access to experimental treatments by HIV-infected patients. New England Journal of Medicine 2002; 346:1373-1382.
84. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, Kotzin BL, Fox L, Chiozzi MH, Leonard JM, Rousseau F, Wade M, D'Arc Roe J, Martinez A & Kessler H. Immunological responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. Journal of Infectious Diseases 1998; 178:70-79.
85. Arnaiz JA, Mallolas J, Podzamczer D, Gerstoft J, Lundgren JD, Cahn P, Fatkenheuer G, d'Arminio Monforte A, Casiro A, Reiss P, Burger DM, Stek M & Gatell J. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003; 17:831-840.
86. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morbidity & Mortality Weekly Report 1998; 47:1-39.
87. Dieleman JP, van Rossum AMC, Stricker BCH, Sturkenboom MCJM, de Groot R, Telgt D, Blok WL, Burger DM, Blijenberg BG, Zietse R & Gyssens IC. Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. Journal of Acquired Immune Deficiency Syndromes 2003; 32:135-142.
88. Gallant JE. Similar 96-week renal safety profile of tenofovir DF versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirinz in antiretroviral naive patients. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy, 14-17 September 2003, Chicago, Ill., USA. Abstract H-840.
89. Carter VM, Hoy JF, Bailey M, Colman PG, Myulasi I & Mijch AM. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Medicine 2001; 2:174-180.
90. Benn P, Ruff C, Sauret V, Copas A, Linney A, Smith C & Edwards SG. Overcoming subjectivity in assessing facial lipoatrophy: is there a role for three-dimensional laser scans? HIV Medicine 2003; 4:325-331.
91. Carr A, Emery S, Law M, Puls R, Lundgren JD & Powderly WG; HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735.
92. Keys AB. Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease. 1980; Cambridge, Mass., USA: Harvard University Press.
93. Coresh J, Toto RD, Kirk KA, Whelton PK, Massry S, Jones C, Agodoa L & Van Lente F. Creatinine clearance as a measure of GFR in screenees for the African-American Study of Kidney Disease and Hypertension pilot study. American Journal of Kidney Disease 1998; 32:32-42.
94. Toto RD, Kirk KA, Coresh J, Jones C, Appel L, Wright J, Campese V, Olutade B & Agodoa L. Evaluation of serum creatinine for estimating glomerular filtration rate in African Americans with hypertensive nephrosclerosis: results from the African-American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Journal of the American Society of Nephrology 1997; 8:279-287.
95. AIDS Clinical Trials Group. Table of Grading and Severity of Adult Adverse Experiences. 1996; Rockville, USA: Division of AIDS; National Institute of Allergy and Infectious Diseases.
96. Eberly LE, Stamler J & Neaton JD. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Archives of Internal Medicine 2003; 163:1077-1083.
97. Smith CJ, Levy I, Sabin CA, Kaya E, Johnson MA & Lipman MCI. Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. HIV Medicine 2004; 5:88-92.
98. Hodgson C, Hodgson L, Murad S, Herman J, Taylor C, Macallan D & Easterbrook PJ. Prevalence of cardiovascular disease (CVD) risk factors in an ethnically diverse HIV-positive population. 8th Annual Conference of the British HIV Association (BHIVA). 18-21 April 2002, York, UK. Abstract P2.
99. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Ellis SG, Lincoff AM & Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. Journal of the American Medical Association 2003; 290:904.
100. Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, Amouyel P, Arveiler D, Ruidavets JB, Reynes J, Bingham A & Raffi F. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clinical Infectious Diseases 2003; 37:292-298.
101. Pirisi M, Toniutto P, Fabris C, Falleti E, Tisminetzky SG, Baralle F & Bartoli E. Factors associated with serum HCV RNA positivity in anti-HCV antibody positive intravenous drug users. Journal of Clinical Epidemiology 1998; 51:423-427.
102. Barrett S, Kieran N, Ryan E, O'Keane JC & Crowe J. Intrahepatic hepatitis C viral RNA status of serum polymerase chain reaction-negative individuals with histological changes on liver biopsy. Hepatology 2001; 33:1496-1502.